Skip to main content
Premium Trial:

Request an Annual Quote

Richard Williams

Richard Williams has become managing director and head of oncology programs at WuXi Nextcode. He joins the company from Grail, where he was lead medical director of the Circulating Cell-Free Genome Atlas program. Prior to that, he held positions in oncology drug development at Amgen and at Puma Technology. Williams holds B.Med.Sc and PhD degrees, as well as bachelor of medicine and bachelor of surgery degrees, from the University of Queensland in Australia.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.